PSA velocity may not be of value in prostate cancer detection
PSA velocity may not be of value in prostate cancer detection
摘要
Prostate cancer is the most prevalent nonskin cancer and is the third leading cause of cancer death in the United States. It is estimated to affect millions of men worldwide and is a significant cause of morbidity and mortality.
Prostate cancer is the most prevalent nonskin cancer and is the third leading cause of cancer death in the United States. It is estimated to affect millions of men worldwide and is a significant cause of morbidity and mortality.
参考文献6
-
1Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Uro/2008; 15: 3866-71.
-
2Vickers A J, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate- specific antigen velocity in prostate cancer detection. J Nat/Cancer/nst 2011; 103: 462-9.
-
3Roobol M J, Kranse R, de Koning H J, Schroder FH. Prostate-specific antigen velocity at Low prostate- specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC. Urology2004; 63: 309-13; discussion 313-5.
-
4D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7.
-
5D'Amico AV, Chen MH, Roehl KA, Catatona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35.
-
6Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007: 99: 1510-5.
